Overview

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Status:
RECRUITING
Trial end date:
2030-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
Phase:
PHASE3
Details
Lead Sponsor:
Dianthus Therapeutics